Adults with plaque PsO who received continuous icotrokinra had superior efficacy outcomes when compared with those who switched to placebo.
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback